Disclosures for "The Impact of OnabotulinumtoxinA on Oral Pain Medication Use and Low-value Care in Patients With Cervical Dystonia"
-
Dr. Jabbari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Jabbari has received publishing royalties from a publication relating to health care.
-
Dr. Dominguez has received personal compensation for serving as an employee of AbbVie. Dr. Dominguez has stock in AbbVie.
-
Dr. Cheng has received personal compensation for serving as an employee of Abbvie.
-
Mr. Manthena has received personal compensation for serving as an employee of Abbvie. Mr. Manthena has stock in Abbvie.
-
Ms. Shah has received personal compensation for serving as an employee of AbbVie. Ms. Shah has stock in AbbVie Inc. An immediate family member of Ms. Shah has received research support from National Institutes of Health.
-
Dr. Rhyne has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Rhyne has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie/Allergan. Dr. Rhyne has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Abbvie/Allergan. Dr. Rhyne has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck.